// App-Quantinova.ai

1039 : Safety of trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (mBC): Final results from KAMILLA Cohorts 1 (global) and 2 (Asia).

Researchers

Presenter

  • Rachel Wuerstlein

Principal Investigators

  • Paul Ellis

  • Filippo Montemurro

  • Antonio Antn Torres

  • Suzette Delaloge

  • Qingyuan Zhang

  • Xiaojia Wang

  • Shusen Wang

  • Shao Zhimin

  • Huiping Li

  • Andhika Rachman

  • Mawin Vongsaisuwon

  • Haiying Liu

  • Simon Fear

  • Claudia Pena-Murillo

  • Carlos H. Barrios

Medical Centers

  • University Hospital Munich, Department of Obstetrics and Gynecology, Breast Center and CCC Munich, LMU, Munich, Germany

  • Guys Hospital and Sarah Cannon Research Institute, London, United Kingdom

  • Fondazione del Piemonte per l'Oncologia, Candiolo Cancer Center, Candiolo, Italy

  • Hospital Miguel Servet, Zaragoza, Spain

  • Institut Gustave-Roussy, Villejuif, France

  • Harbin Medical University Caner Hospital, Haerbing, China

  • Zhejiang Cancer Hospital, Hangzhou, China

  • Sun Yat-Sen University Cancer Center, Guangdzhou, Guangdong, China

  • Fudan University Shanghai Cancer Center, Shanghai, China

  • Beijing Sanhuan Cancer Hospital, Beijing, China

  • MRCCC Siloam Semanggi Hospital, Jakarta, Indonesia

  • King Chulalongkorn Memorial Hospital, Bangkok, Thailand

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Oncology Research Center HSL, PUCRS, Latin American Cooperative Oncology Group, Porto Alegre, Brazil

Locations

  • Germany

  • United Kingdom

  • Italy

  • Spain

  • France

  • China

  • Indonesia

  • Thailand

  • Switzerland

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Breast cancer

  • Thrombocytopenia

  • Pulmonary alveolar proteinosis

  • Solid malignancies

Biomarkers

  • Serine Peptidase Inhibitor, Kazal Type 1

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab emtansine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01702571

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved